(Q64226343)

1

0 references

Kalin Narov

2

0 references

Jian Yang

3

0 references

Julian R Sampson

4

0 references

Ming Hong Shen

describes a project that uses

5

0 references

language of work or name

English

0 references

publication date

February 2019

0 references

published in

Neoplasia

0 references

volume

21

0 references

issue

2

0 references

page(s)

230-238

0 references

ImageJ

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6324218/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Identification and characterization of the tuberous sclerosis gene on chromosome 16

1 reference

12 December 2020

Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors

1 reference

12 December 2020

Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background

1 reference

12 December 2020

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

12 December 2020

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

1 reference

12 December 2020

A complex interplay between Akt, TSC2 and the two mTOR complexes

1 reference

12 December 2020

Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply

1 reference

12 December 2020

Regulation of cancer cell metabolism

1 reference

12 December 2020

mTORC2 is required for proliferation and survival of TSC2-null cells

1 reference

12 December 2020

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

1 reference

12 December 2020

T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis.

1 reference

12 December 2020

Glucose deprivation in tuberous sclerosis complex-related tumors

1 reference

12 December 2020

A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside

1 reference

12 December 2020

Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester

1 reference

12 December 2020

System-wide immunohistochemical analysis of protein co-localization

1 reference

12 December 2020

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4

1 reference

12 December 2020

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

1 reference

12 December 2020

Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin

1 reference

12 December 2020

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

1 reference

12 December 2020

A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex

1 reference

12 December 2020

Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate

1 reference

12 December 2020

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

1 reference

12 December 2020

3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.

1 reference

12 December 2020

Inhibitory effects of 3-bromopyruvate in human nasopharyngeal carcinoma cells

1 reference

12 December 2020

Cancer metabolism: a therapeutic perspective

1 reference

12 December 2020

mTORC2 controls cancer cell survival by modulating gluconeogenesis

1 reference

12 December 2020

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2+/- Mice Is Superior to Everolimus Alone

1 reference

12 December 2020

The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis

1 reference

12 December 2020

Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer

1 reference

12 December 2020

Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging

1 reference

12 December 2020

Cabozantinib: A Multi-targeted Oral Tyrosine Kinase Inhibitor

1 reference

12 December 2020

Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.

1 reference

12 December 2020

Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer.

1 reference

12 December 2020